Article

64 views
KEY POINTS Praluent is a cholesterol-lowering monoclonal antibody, significantly reduces the combined risk of cardiovascular problems and related deaths in ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

KEY POINTS Praluent is a cholesterol-lowering monoclonal antibody, significantly reduces the combined risk of cardiovascular problems and related deaths in ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in MARKET INSIGHTS


MARKET INSIGHTS

Billion Dollars Healthcare Startups (2018)

KEY POINTS A unicorn is a startup company with a current valuation of US$1 billion or more. Medgenera DATALABS has ...

MARKET INSIGHTS

Pharma Giants Gradually Embracing Digital Healthcare Technologies

Big pharma players including Novartis, Roche, Pfizer, Sanofi are embracing digital technologies to deliver better to the patients. FDA’S 2018 Strategic Policy Roadmap indicates increasing number of digital health clearances in coming times with revised regulatory processes.

M & A

Is Novartis Betting High to Give First FDA-Approved Gene Therapy for Spinal Muscular Atrophy?

Novartis bets high by acquiring the non-earning US-based gene therapy firm AveXis for $8.7 billion. But, AveXis' novel gene therapy- AVXS-101 could be a “game-changing” treatment for SMA patients and could turn out to be a potential blockbuster for Novartis, if approved.

MARKET INSIGHTS

Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)

KEY POINTS Ozone depletion, greenhouse gas-induced global warming, rising earth temperature is interacting to put a severe effect on human ...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.